The article is available free online.
Denormalization is a strategy for changing social norms and reinforcing a public perception of tobacco use as a health-compromising, socially unacceptable behavior. Karen Calabro, DrPH, Ramara Costello, and Alexander Prokhorov, MD, PhD , from M.D. Anderson Cancer Center (Houston, Texas), describe several ways pediatricians and other medical professionals can help their patients and their communities to see tobacco use as undesirable: through direct communication with patients and their families; by providing information and referrals for tobacco prevention and cessation programs; by setting personal examples of a tobacco-free lifestyle; and by advocating for stronger public policies aimed at reducing tobacco use and exposure. In the article entitled, “Denormalization of Tobacco Use and the Role of the Pediatric Health-Care Provider,” the authors assert that healthcare professionals can have a significant, positive impact on children’s health by working to denormalize tobacco use.
“For years big tobacco has promoted its toxic product as what popular, successful, glamorous, attractive, confident, athletic, and independent people do. It is time to start re-claiming the truth. Use of a product that hurts you and everyone around you is not something that should be glamorized. Implementation of strategies to change public perceptions about tobacco have had substantial impact on reducing youth smoking–and have been vigorously fought by the tobacco industry. Pediatricians, as advocates for children’s health, need to send strong messages to their patients and their communities to counter the tobacco industry deceptions,” says Harold Farber, MD, MSPH, Editor of Pediatric Allergy, Immunology, & Pulmonology, and Associate Professor of Pediatrics, Section of Pulmonology, Baylor College of Medicine, Houston, TX.
Pediatric Allergy, Immunology, & Pulmonology is a quarterly journal published in print and online. The Journal has expanded its coverage to synthesize the pulmonary, allergy, and immunology communities in the advancement of the respiratory health of children. The Journal provides comprehensive coverage to further the understanding, and optimize the treatment, of some of the most common and costly chronic illnesses in children. It includes original translational, clinical and epidemiologic research, public health, quality improvement, and case control studies, patient education research, and the latest research and standards of care for functional and genetic immune deficiencies and interstitial lung diseases. Table of contents and a free sample issue may be viewed online.
Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Aerosol Medicine and Pulmonary Drug Delivery and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 60 journals, books, and newsmagazines is available at our website.
Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101